image

Supporting Rett Syndrome and NF research through the Children’s Hospital at Westmead on Thursday 26 September 2019

At Yieldbroker, we’re grateful for the opportunity to contribute to our local community. Every year we carefully choose a small number of initiatives to support; most often we choose those which have a striking effect on people’s quality of life, yet have little support or funding already.

We’re grateful to all our clients and employees whose generosity on Charity Day has helped us make a big impact on the charities we support.

A little about
this year’s initiatives

  • Rett Syndrome

    Our primary efforts this year will be directed at raising awareness and funds for Rett Syndrome (RTT).  RTT which is seen almost exclusively in females, is a genetic disorder in which the brain does not mature in the way it should. For most affected children, their early development appears normal but then slows down or suddenly halts. This period of their lives can be marked by very serious challenges including loss of communication, mobility, intellectual disability and breathing problems.

    Rett Syndrome has been an active area of research at The Children’s Hospital at Westmead, where the focus is to develop and apply advanced gene-editing technologies to discover a cure for the syndrome.

    Brett Anslow (Colonial) has a  daughter, Holly, with Rett Syndrome, and at the current rate of funding research to find a cure will take between 5 and 10 years. With increased fundraising from Yieldbroker, Holly may see a cure in less time!

    Yieldbroker’s contribution will be applied to directly fund the gene-editing research.

    Learn more
  • Neurofibromatosis (NF) at Westmead Children’s Hospital

    This disease affects approximately 10,000 people across Australia. Sufferers of NF often develop tumours that can cause severe disfigurement, blindness and deafness.  Sadly, such disfigurement occurring in children also leads to a high suicide rate during formative years.

    Yieldbroker’s contribution will be used for research and clinical trials that reduce the life-threatening tumours that can form as part of the disease’s progression.

    Learn more

Find out more

For more information about the initiatives Yieldbroker is supporting, please read our stories here.

Read here